Oncotarget

Research Papers:

A novel prognostic score model incorporating CDGSH iron sulfur domain2 (CISD2) predicts risk of disease progression in laryngeal squamous cell carcinoma

Lin Yang, Shaodong Hong, Yan Wang, Zhenyu He, Shaobo Liang, Haiyang Chen, Shasha He, Shu Wu, Libing Song and Yong Chen _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:22720-22732. https://doi.org/10.18632/oncotarget.8150

Metrics: PDF 2332 views  |   HTML 2682 views  |   ?  


Abstract

Lin Yang1,2,3,*, Shaodong Hong1,2,3,*, Yan Wang1,2,3,*, Zhenyu He1,2,3, Shaobo Liang4, Haiyang Chen5, Shasha He1,2,3, Shu Wu1,2,3, Libing Song1,2,3, Yong Chen1,2,3

1Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China

2State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China

3Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China

4The First Hospital of Foshan, Foshan 528000, China

5The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510060, China

*These authors contributed equally to this work

Correspondence to:

Yong Chen, e-mail: [email protected]

Keywords: CDGSH iron sulfur domain2 (CISD2), laryngeal squamous cell carcinoma (LSCC), progression free survival (PFS), biomarker

Received: October 09, 2015     Accepted: February 23, 2016     Published: March 17, 2016

ABSTRACT

Background: The role of CDGSH iron sulfur domain 2 (CISD2) in laryngeal squamous cell carcinoma (LSCC) remains unclear.

Results: CISD2 were up-regulated in LSCC tissues compared with adjacent noncancerous tissues both at mRNA and protein levels. CISD2 was significantly correlated with T stage, lymph node metastasis, clinical stage and disease progression. A prognostic model (C-N model) for PFS was subsequently constructed based on independent prognostic factors including CISD2 and N classification. This model significantly divided LSCC patients into three risk subgroups and was more accurate than the prediction efficacy of TNM classification in the training cohort (C-index, 0.710 vs 0.602, P = 0.027) and validation cohort (C-index, 0.719 vs 0.578, P = 0.014).

Methods: Real-time PCR and Western blotting were employed to examine the expression of CISD2 in eight fresh paired LSCC samples. Immunohistochemistry was performed to assess CISD2 expression in 490 paraffin-embedded archived LSCC samples. A prognostic model for progression-free survival (PFS) was built using independent factors. The concordance index (C-Index) was used to evaluate the prognostic ability of the model.

Conclusions: CISD2 was up-regulated in LSCC. The novel C-N model, which includes CISD2 levels and N classification, is more accurate than conventional TNM classification for predicting PFS in LSCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8150